Table 1.
Patient characteristics
| Characteristic | Value |
|---|---|
| Age (yr) | 46 (27–66) |
| <40 | 8 (5.6) |
| ≥40 | 136 (94.4) |
| Tumor size | |
| T1 | 65 (45.1) |
| T2 | 74 (51.4) |
| T3 | 5 (3.5) |
| Number of positive lymph nodes | |
| 1 | 80 (55.6) |
| 2 | 46 (31.9) |
| 3 | 18 (12.5) |
| Number of dissected lymph nodes | 17 (5–43) |
| ≤20 | 85 (59.0) |
| >20 | 59 (41.0) |
| LNR | 0.09 (0.02–0.23) |
| Low (≤0.15) | 130 (90.3) |
| High (>0.15) | 14 (9.7) |
| Operation type | |
| Total mastectomy | 88 (61.1) |
| Partial mastectomy | 56 (38.9) |
| Local radiotherapy | |
| No | 85 (59.0) |
| Yes | 59 (41.0) |
| Regional radiotherapy | |
| No | 132 (91.7) |
| Yes | 12 (8.3) |
| Pathology | |
| IDC | 139 (96.5) |
| Other | 5 (3.5) |
| Histologic grade | |
| I & II | 62 (43.1) |
| III | 72 (50.0) |
| Unknown | 10 (6.9) |
| LVI | |
| No | 57 (39.6) |
| Yes | 74 (51.4) |
| Unknown | 13 (9.0) |
| ECE | |
| No | 100 (69.4) |
| Yes | 21 (14.6) |
| Unknown | 23 (16.0) |
| Resection margin (mm) | |
| Close (<2) | 21 (14.6) |
| Clear (≥2) | 122 (84.7) |
| Unknown | 1 (0.7) |
| Molecular subtype | |
| Luminal Aa) | 63 (43.8) |
| Luminal Bb) | 41 (28.5) |
| HER2-enrichedc) | 7 (4.9) |
| Triple negatived) | 22 (15.3) |
| Unknown | 11 (7.6) |
| Adjuvant hormone therapy | |
| No | 31 (21.5) |
| Yes | 113 (78.5) |
Values are presented as median (range) or number (%).
LNR, lymph node ratio; IDC, invasive ductal carcinoma; LVI, lymphovascular invasion; ECE, extracapsular extension.
a)
Hormone receptor-positive, HER2-negative and Ki67 <14%.
b)
Hormone receptor-positive & Ki67 ≥14% or HER2-positive.
c)
Hormone receptor-negative and HER2-positive.
d)
Hormone receptor-negative and HER2-negative.